Latest Articles
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer - OncLive
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer OncLive
Published: Aug. 26, 2025, 3:01 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - Yahoo Finance
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Yahoo Finance
Published: Aug. 26, 2025, noon
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial - Nature
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial Nature
Published: Aug. 26, 2025, 11:43 a.m.
Mum, 31, given terminal cancer diagnosis 'in shock' after two-year 'misdiagnosis' - Birmingham Live
Mum, 31, given terminal cancer diagnosis 'in shock' after two-year 'misdiagnosis' Birmingham Live
Published: Aug. 26, 2025, 9:21 a.m.
Mum discovers terminal cancer after 2-year misdiagnosis - upday News
Mum discovers terminal cancer after 2-year misdiagnosis upday News
Published: Aug. 26, 2025, 9:15 a.m.
GSK Enters India’s Oncology Space With Jemperli & Zejula For Women’s Cancers - BW Healthcare
GSK Enters India’s Oncology Space With Jemperli & Zejula For Women’s Cancers BW Healthcare
Published: Aug. 26, 2025, 8:55 a.m.
GSK Enters India’s Oncology Space With Jemperli & Zejula For Women’s Cancers - BW Healthcare World
GSK Enters India’s Oncology Space With Jemperli & Zejula For Women’s Cancers BW Healthcare World
Published: Aug. 26, 2025, 8:55 a.m.
GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor - connectedtoindia.com
GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor connectedtoindia.com
Published: Aug. 26, 2025, 4:39 a.m.
GSK forays into Oncology in India with Jemperli and Zejula, Bringing Precision Therapies for Gynaecological Cancers - India Education Diary
GSK forays into Oncology in India with Jemperli and Zejula, Bringing Precision Therapies for Gynaecological Cancers India Education Diary
Published: Aug. 25, 2025, 3:28 p.m.
GSK forays into oncology in India bringing precision therapies for gynaecological cancers - BioSpectrum India
GSK forays into oncology in India bringing precision therapies for gynaecological cancers BioSpectrum India
Published: Aug. 25, 2025, 2:19 p.m.
Link copied to clipboard!